Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)

October 1, 2026 3:10 PM EDT Send to a Friend
Baird analyst Brian Skorney reiterated a Neutral rating and $761.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst comments "Positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login